• Calu-3人肺腺癌细胞(STR鉴定正确)

    价 格:¥1800

    期 货👐:现货(冻存管发2支)

    保藏中心:BTCC

    资源编号:BTCC-1035

    产地🧘🏼:中国

    套 餐:

    T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

    详细资料说明书下载质检报告(COA)

    Cell line nameCalu-3
    SynonymsCaLu-3; CALU-3; Calu 3; Calu3; CALU3
    AccessionBTCC-1035
    Resource Identification InitiativeTo cite this cell line use: Calu-3 (BTCC-1035)
    CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
    Part of: COSMIC cell lines project.
    Part of: KuDOS 95 cell line panel.
    Part of: MD Anderson Cell Lines Project.
    From: Memorial Sloan Kettering Cancer Center; New York; USA.
    Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-533.
    Population: Caucasian.
    Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474).
    Doubling time: 35 hours (Note=In RPMI 1640 + 10% FBS), 45 hours (Note=In ACL-3), 37 hours (Note=In ACL-3+BSA) (PubMed=3940644); 40.1 hours (PubMed=29681454); ~84 hours (PubMed=34339474).
    Microsatellite instability: Stable (MSS) (Sanger).
    Omics: Array-based CGH.
    Omics: Cell surface proteome.
    Omics: Deep exome analysis.
    Omics: Deep quantitative proteome analysis.
    Omics: DNA methylation analysis.
    Omics: Protein expression by reverse-phase protein arrays.
    Omics: SNP array analysis.
    Omics: Transcriptome analysis by microarray.
    Omics: Transcriptome analysis by RNAseq.
    Misspelling: CALV3; Cosmic=1434969.
    Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
    Sequence variations
    • Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (PubMed=20557307; ATCC).
    HLA typingSource: PubMed=26589293
    Class I
    HLA-AA*24:02,68:01
    HLA-BB*07:02,51:01
    HLA-CC*15:02,15:02
    Genome ancestrySource: PubMed=30894373

    Origin% genome


    African0.63
    Native American0
    East Asian, North2.09
    East Asian, South0
    South Asian0
    European, North67.76
    European, South29.51
    DiseaseLung adenocarcinoma (NCIt: C3512)
    Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
    HierarchyChildren:



    CVCL_B0ZC (Abcam Calu-3 TMPRSS2 KO)CVCL_YZ47 (Calu-3 2B4)CVCL_EQ19 (Calu3-GemR)
    Sex of cellMale
    Age at sampling25Y
    CategoryCancer cell line
    STR profileSource(s): AddexBio; ATCC; CCRID; Cosmic-CLP; KCLB; PubMed=25877200

    Markers:
    AmelogeninX
    CSF1PO11,12
    D2S133819
    D3S135815,18
    D5S81811
    D7S82010,11
    D8S117911,15
    D13S31712
    D16S53912,14
    D18S5114,17
    D19S43312,13
    D21S1128,30
    FGA25
    Penta D9,16
    Penta E5,21
    TH016,9.3
    TPOX8
    vWA16,17

    Run an STR similarity search on this cell line
    Web pageshttps://en.wikipedia.org/wiki/Calu-3
    https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-604.html
    https://www.mskcc.org/research-advantage/support/technology/tangible-material/calu-3-human-lung-cell-line
    https://tcpaportal.org/mclp/
    Publications

    PubMed=327080; DOI=10.1093/jnci/59.1.221
    Fogh J., Fogh J.M., Orfeo T.
    One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
    J. Natl. Cancer Inst. 59:221-226(1977)

    PubMed=7459858
    Rousset M., Zweibaum A., Fogh J.
    Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
    Cancer Res. 41:1165-1170(1981)

    PubMed=6220172
    Dracopoli N.C., Fogh J.
    Polymorphic enzyme analysis of cultured human tumor cell lines.
    J. Natl. Cancer Inst. 70:469-476(1983)

    PubMed=3518877; DOI=10.3109/07357908609038260
    Fogh J.
    Human tumor lines for cancer research.
    Cancer Invest. 4:157-184(1986)

    PubMed=3940644
    Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
    Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
    Cancer Res. 46:798-806(1986)

    PubMed=3129183
    Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.
    Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas.
    Cancer Res. 48:2674-2677(1988)

    PubMed=3335022
    Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
    Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
    Cancer Res. 48:589-601(1988)

    PubMed=7515578; DOI=10.1152/ajplung.1994.266.5.L493
    Shen B.Q., Finkbeiner W.E., Wine J.J., Mrsny R.J., Widdicombe J.H.
    Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl-secretion.
    Am. J. Physiol. 266:L493-L501(1994)

    PubMed=9636188; DOI=10.1073/pnas.95.13.7556
    Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D.
    Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
    Proc. Natl. Acad. Sci. U.S.A. 95:7556-7561(1998)

    PubMed=10523844; DOI=10.1038/sj.onc.1202957
    Agochiya M., Brunton V.G., Owens D.W., Parkinson E.K., Paraskeva C., Keith W.N., Frame M.C.
    Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
    Oncogene 18:5646-5653(1999)

    PubMed=11064206; DOI=10.1016/S0378-5173(00)00452-X
    Foster K.A., Avery M.L., Yazdanian M., Audus K.L.
    Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery.
    Int. J. Pharm. 208:1-11(2000)

    PubMed=15463957; DOI=10.1016/j.jcf.2004.05.040
    Gruenert D.C., Willems M., Cassiman J.-J., Frizzell R.A.
    Established cell lines used in cystic fibrosis research.
    J. Cyst. Fibros. 3:191-196(2004)

    PubMed=17483357; DOI=10.1158/0008-5472.CAN-06-4495
    Tooker P., Yen W.-C., Ng S.-C., Negro-Vilar A., Hermann T.W.
    Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
    Cancer Res. 67:4425-4433(2007)

    PubMed=18083107; DOI=10.1016/j.cell.2007.11.025
    Rikova K., Guo A.-L., Zeng Q.-F., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y.-R., Tan Z.-P., Stokes M.P., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.-M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D.-Q., Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
    Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
    Cell 131:1190-1203(2007)

    PubMed=19153074; DOI=10.1093/hmg/ddp034
    Medina P.P., Castillo S.D., Blanco S., Sanz-Garcia M., Largo C., Alvarez S., Yokota J., Gonzalez-Neira A., Benitez J., Clevers H.C., Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.
    The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.
    Hum. Mol. Genet. 18:1343-1352(2009)

    PubMed=19472407; DOI=10.1002/humu.21028
    Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
    A gene-alteration profile of human lung cancer cell lines.
    Hum. Mutat. 30:1199-1206(2009)

    PubMed=20090954; DOI=10.1371/journal.pone.0008729
    Yoshikawa T., Hill T.E., Yoshikawa N., Popov V.L., Galindo C.L., Garner H.R., Peters C.J., Tseng C.-T.
    Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection.
    PLoS ONE 5:E8729-E8729(2010)

    PubMed=20164919; DOI=10.1038/nature08768
    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
    Signatures of mutation and selection in the cancer genome.
    Nature 463:893-898(2010)

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
    Cancer Res. 70:2158-2164(2010)

    PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x
    Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
    Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
    Cancer Sci. 101:1891-1896(2010)

    PubMed=22460905; DOI=10.1038/nature11003
    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature 483:603-607(2012)

    PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112
    Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
    Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Cancer Discov. 2:798-811(2012)

    PubMed=24207061; DOI=10.1186/1559-0275-10-16
    Cerciello F., Choi M., Nicastri A., Bausch-Fluck D., Ziegler A., Vitek O., Felley-Bosco E., Stahel R.A., Aebersold R., Wollscheid B.
    Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.
    Clin. Proteomics 10:16.1-16.12(2013)

    PubMed=25485619; DOI=10.1038/nbt.3080
    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
    A comprehensive transcriptional portrait of human cancer cell lines.
    Nat. Biotechnol. 33:306-312(2015)

    PubMed=25555374; DOI=10.1016/j.ejps.2014.12.017
    Kreft M.E., Jerman U.D., Lasic E., Hevir-Kene N., Rizner T.L., Peternel L., Kristan K.
    The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function.
    Eur. J. Pharm. Sci. 69:1-9(2015)

    PubMed=25894527; DOI=10.1371/journal.pone.0121314
    Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
    A mass spectrometric-derived cell surface protein atlas.
    PLoS ONE 10:E0121314-E0121314(2015)

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5
    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
    Genome Med. 7:118.1-118.7(2015)

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
    A landscape of pharmacogenomic interactions in cancer.
    Cell 166:740-754(2016)

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
    Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
    Characterization of human cancer cell lines by reverse-phase protein arrays.
    Cancer Cell 31:225-239(2017)

    PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
    McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., Deberardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
    Chemistry-first approach for nomination of personalized treatment in lung cancer.
    Cell 173:864-878.e29(2018)

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
    Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
    Cancer Res. 79:1263-1273(2019)

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3
    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
    Next-generation characterization of the Cancer Cell Line Encyclopedia.
    Nature 569:503-508(2019)

    PubMed=34339474; DOI=10.1371/journal.pone.0255622
    Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V., Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y., Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.
    Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies.
    PLoS ONE 16:E0255622-E0255622(2021)

    PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
    Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
    Pan-cancer proteomic map of 949 human cell lines.
    Cancer Cell 40:835-849.e8(2022)

    Cross-references
    Cell line databases/resourcesCLO; CLO_0002192
    CLDB; cl634
    CLDB; cl635
    CLDB; cl5176
    CCRID; 1101HUM-PUMC000032
    CCRID; 1101HUM-PUMC000329
    CCRID; 3101HUMTCHu157
    CCRID; 4201HUM-CCTCC00647
    Cell_Model_Passport; SIDM00922
    Cosmic-CLP; 687777
    DepMap; ACH-000392
    IGRhCellID; Calu3
    LINCS_HMS; 50010
    LINCS_LDP; LCL-1631
    Lonza; 342
    TOKU-E; 768
    Anatomy/cell type resourcesBTO; BTO:0002750
    Biological sample resourcesBioSample; SAMN03471552
    BioSample; SAMN10988517
    Cell line collections (Providers)Abcam; ab275465
    AddexBio; C0016001/30
    ATCC; HTB-55
    BCRJ; 0264
    CLS; 305032
    IZSLER; BS TCL 103
    KCLB; 30055
    Chemistry resourcesChEMBL-Cells; CHEMBL3307390
    ChEMBL-Targets; CHEMBL614534
    GDSC; 687777
    PharmacoDB; Calu3_179_2019
    PubChem_Cell_line; CVCL_0609
    Encyclopedic resourcesWikidata; Q52392355
    Experimental variables resourcesEFO; EFO_0002819

    更多>>相关产品

    总部地址🔡:北京市怀柔区渤海镇怀沙路536号

    关注杏鑫
    在线咨询
    在线客服
    电话咨询
    微信客服
    返回顶部
    杏鑫娱乐专业提供🧑‍🦽‍➡️:杏鑫娱乐🚛、杏鑫杏鑫平台等服务,提供最新官网平台、地址、注册、登陆、登录、入口、全站、网站、网页、网址、娱乐、手机版、app、下载、欧洲杯、欧冠、nba、世界杯、英超等,界面美观优质完美,安全稳定,服务一流,杏鑫娱乐欢迎您。